Joint Formulary & PAD

Exemestane - Breast cancer

You are here : Home > Formulary Search > Exemestane - Breast cancer

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :
Important

1st month supply from specialist team before request for primary care prescribing

Documentation

Shared Care
Aromatase inhibitors in breast cancer - Amber Star information sheet SWSH Cancer Network - February

PAD Profile

ChemicalSubstance :
Exemestane
Indication :
Breast cancer
Group Name :
Keywords :
Aromatase Inhibitors
Brand Names Include :
Aromasin
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

03 May 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC Exemestane has been considered by the PCN and has been assigned an AMBER STAR traffic light status.

NOTE - the branded product, Aromasin, was considered BLACK at the PCN in May 2017.

Other Indications

Below are listed other indications that Exemestane is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Breast cancer.